Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 80Neoplasms 14Neoplasm Metastasis 14Brain Neoplasms 9Breast Neoplasms, Male 7Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 5Stomach Neoplasms 4Urinary Bladder Neoplasms 3Salivary Gland Neoplasms 3Recurrence 3Prostatic Neoplasms 3Inflammatory Breast Neoplasms 3Gallbladder Neoplasms 3Colorectal Neoplasms 3Carcinoma, Squamous Cell 3Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 2Ovarian Neoplasms 2Glioma 2Glioblastoma 2Ependymoma 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Bile Duct Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Thymoma 1Spinal Cord Neoplasms 1

Interventions

Radiotherapy 1Oxaliplatin 1Lapatinib 1Fluorouracil 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × HER2 Positive Esophagogastric Cancer × Lapatinib × Clear all
NCT01769508 2016-06-13

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

SCRI Development Innovations, LLC

Phase 2 Terminated
12 enrolled 8 charts
Gastrointestinal

HER2 Positive Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡